コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ious lines of therapy (including <=1 line of systemic chemotherapy).
2 ant chemotherapy also received postoperative systemic chemotherapy.
3 ents, despite the administration of adjuvant systemic chemotherapy.
4 ression reduction (IR) followed by immediate systemic chemotherapy.
5 rnally-cooled electrodes in association with systemic chemotherapy.
6 Sixty-eight (99%) received systemic chemotherapy.
7 matic disease sites as well as intra-CSF and systemic chemotherapy.
8 matic disease sites as well as intra-CSF and systemic chemotherapy.
9 anced pancreatic NETs after failure of prior systemic chemotherapy.
10 and radiographic complete remission (CR) to systemic chemotherapy.
11 laced by intensive intrathecal treatment and systemic chemotherapy.
12 reduction in febrile neutropenia (FN) after systemic chemotherapy.
13 prove the selection of patients for adjuvant systemic chemotherapy.
14 umoral injections of rF-mCD40L together with systemic chemotherapy.
15 e patients, the asymptomatic BM responded to systemic chemotherapy.
16 (at diagnosis of SCLC) and after first-line systemic chemotherapy.
17 small-cell lung cancer (SCLC) to first-line systemic chemotherapy.
18 to inform decisions on withholding adjuvant systemic chemotherapy.
19 ed therapy with cystectomy and perioperative systemic chemotherapy.
20 d less than a quarter of patients respond to systemic chemotherapy.
21 on, given the improvement in the efficacy of systemic chemotherapy.
22 ume of the brain and spine), with or without systemic chemotherapy.
23 atment that includes surgery, radiation, and systemic chemotherapy.
24 ntriculoatrial shunts, prior craniotomy, and systemic chemotherapy.
25 agent in NSCLC should be in combination with systemic chemotherapy.
26 long-term cognitive deficits associated with systemic chemotherapy.
27 who received HAI also received perioperative systemic chemotherapy.
28 asome inhibition as an important adjuvant to systemic chemotherapy.
29 irty-three patients (75%) had received prior systemic chemotherapy.
30 sed patient with HCC had previously received systemic chemotherapy.
31 lized disease, (2) interferon-alpha, and (3) systemic chemotherapy.
32 primary site; more recently, it has included systemic chemotherapy.
33 ents had progressive disease following prior systemic chemotherapy.
34 chemotherapy and two more cycles of the same systemic chemotherapy.
35 up C, development of brain metastases during systemic chemotherapy.
36 volumes to higher doses in conjunction with systemic chemotherapy.
37 a is a rare malignancy with poor response to systemic chemotherapy.
38 t surgical resection; three of them also had systemic chemotherapy.
39 ne, prophylactic chest wall radiotherapy and systemic chemotherapy.
40 rgical resection, whole-brain radiation, and systemic chemotherapy.
41 sis and require a combination of surgery and systemic chemotherapy.
42 f patients are spared the adverse effects of systemic chemotherapy.
43 ents who underwent surgery and postoperative systemic chemotherapy.
44 who received both surgery and postoperative systemic chemotherapy.
45 tempered by altering the dosing schedule of systemic chemotherapy.
46 ed efficacy and reduced toxicity compared to systemic chemotherapy.
47 apeutic concentration at the tumor site with systemic chemotherapy.
48 ients with the goal of providing time off of systemic chemotherapy.
49 al in patients with IU-CRLM treated with HAI/systemic chemotherapy.
50 metastases in patients receiving first-line systemic chemotherapy.
51 as shown multifarious advantages compared to systemic chemotherapy.
52 r patients with TRIL who have received prior systemic chemotherapy.
53 disease, implications for surveillance, and systemic chemotherapy.
54 ecific likelihood of receiving postoperative systemic chemotherapy.
55 A total of 40 patients received systemic chemotherapy.
56 redict the response of human lung cancers to systemic chemotherapy.
57 ersus >/= 25%); 2) prior platinum-containing systemic chemotherapy; 3) embolization of segments 5-8 v
60 ed by systemic chemotherapy or only adjuvant systemic chemotherapy (69.6% v 70.9%, log-rank; P = .692
62 Postoperative HAI oxaliplatin combined with systemic chemotherapy after curatively intended surgery
63 , but not age, CNS malignant cancer type, or systemic chemotherapy agent, was associated with maculop
68 T FINDINGS: Improved prognosis compared with systemic chemotherapy alone has recently been demonstrat
69 Factors associated with achieving CR with systemic chemotherapy alone included FOLFOX4 treatment,
71 ITCs, adjuvant therapy (radiotherapy alone, systemic chemotherapy alone, or both) was associated wit
72 and intraperitoneal chemotherapy (IPC) over systemic chemotherapy alone, the treatment of peritoneal
75 s require vascular access devices (VADs) for systemic chemotherapies and for supportive treatments, i
76 percent in the group treated with local plus systemic chemotherapy and 72 percent in the group given
77 ases are used to discuss the current role of systemic chemotherapy and allogeneic stem cell transplan
79 d randomly assigned (1:1) to either adjuvant systemic chemotherapy and HIPEC (n = 100) or adjuvant sy
80 treatment of the CNS included both high-dose systemic chemotherapy and intrathecal therapy, in contra
83 ents who had failed to respond adequately to systemic chemotherapy and local treatment where appropri
84 Finally, we review the progress made with systemic chemotherapy and novel therapeutics, including
86 therapy were randomized to receive intensive systemic chemotherapy and presymptomatic CNS therapy tha
87 -term outcomes of pleurectomy decortication, systemic chemotherapy and prophylactic radiotherapy in p
89 ciation was independent of the use of modern systemic chemotherapy and remained in propensity score a
91 ced non-small cell lung cancer has been with systemic chemotherapy and usually consists of a platinum
92 tes of extracranial disease who failed early systemic chemotherapy and were able to receive SBRT and
95 to relieve pain when used concurrently with systemic chemotherapy and/or hormonal therapy, since it
96 patients enrolled, 117 had received no prior systemic chemotherapy, and 34 had received prior chemoth
97 and antibody therapies such as alemtuzumab, systemic chemotherapy, and allogeneic transplantation.
98 ternal beam radiotherapy, reduced the use of systemic chemotherapy, and diminished enucleations by 90
99 mptoms, inability to tolerate surgery and/or systemic chemotherapy, and history of another cancer wer
101 for 55 patients: 39 patients (78%) received systemic chemotherapy, and of the 16 patients (28%) who
102 unilateral RB; 43 patients (63.0%) received systemic chemotherapy; and 57 patients (78.1%) underwent
103 bidities, and treatment modalities including systemic chemotherapy, antiangiogenic therapy, and hospi
108 e to target these pathways concurrently with systemic chemotherapy as a strategy to improve the clini
109 er received significantly more postoperative systemic chemotherapy at all stages, but they experience
112 The vast majority of cTSH patients received systemic chemotherapy between stages, including hepatic
113 cancer or lymphoma who had been treated with systemic chemotherapy (breast, n = 141, age = 57.0 +/- 1
114 ent colorectal cancer (CRC) patients require systemic chemotherapy, but the therapeutic options of ta
117 e the risk of subsequent metastatic disease, systemic chemotherapy can be introduced early during the
118 from this study support the hypothesis that systemic chemotherapy can have a negative impact on cogn
119 l injection of CpG oligodeoxynucleotide plus systemic chemotherapy can induce a T-cell immune respons
120 oreductive surgery embedded in perioperative systemic chemotherapy, can provide cure in selected pati
121 ase II trials have demonstrated tolerance to systemic chemotherapy; chemotherapy plus radiation prior
122 oma even in localized disease whereas IR and systemic chemotherapy (CHOP-21) could achieve lasting co
123 in-related PROM was infrequently utilized in systemic chemotherapy clinical trials (79 studies [20.0%
125 nal Cancer Data Base who received multiagent systemic chemotherapy combined with high-intensity versu
126 8 times more likely to receive postoperative systemic chemotherapy compared with older patients (65-7
128 of patients and fewer patients who received systemic chemotherapy developed pineoblastoma, possibly
130 l mucin debulking, adenocarcinoma histology, systemic chemotherapy, diffuse IP disease at presentatio
132 otrexate, as well as the roles of additional systemic chemotherapy drugs, intrathecal therapy, and cr
133 to inform decisions on withholding adjuvant systemic chemotherapy due to its ability to identify a g
134 horts differed significantly in preoperative systemic chemotherapy exposure, node-positive primary st
135 treated with OAC after prior treatment with systemic chemotherapy, external beam radiation, or both
137 ents received two cycles of bolus 5-FU-based systemic chemotherapy followed by pelvic radiation thera
140 Doxorubicin (DOX) is the standard first-line systemic chemotherapy for advanced soft-tissue sarcoma,
146 with an improved survival, as compared with systemic chemotherapy for peritoneal carcinomatosis from
152 ecular subtypes may increase the efficacy of systemic chemotherapy-free HER2-targeted approaches.
154 univariate analysis, the use of neoadjuvant systemic chemotherapy had a significant positive prognos
161 cancer (CRC) can be rendered resectable with systemic chemotherapy in approximately 20% of cases.
162 rove survival, advances have been made using systemic chemotherapy in both the perioperative settings
163 h IT mafosfamide administered with intensive systemic chemotherapy in children younger than 3 years w
164 Most patients can receive radiotherapy and systemic chemotherapy in due time and receive further th
165 Evidence supports the safety and efficacy of systemic chemotherapy in fit older patients motivated en
166 mersen sodium) could improve the efficacy of systemic chemotherapy in patients with advanced melanoma
167 d to guide decisions on withholding adjuvant systemic chemotherapy in patients with hormone receptor-
168 is prospective randomized crossover trial of systemic chemotherapy in patients with low-grade mucinou
170 s with a PS of 2 (PS2); thus, the benefit of systemic chemotherapy in PS2 patients is uncertain.
172 erial chemoembolization and/or perioperative systemic chemotherapy in the treatment of advanced HCC t
173 c antibody in combination with standard-dose systemic chemotherapy in the treatment of indolent B-cel
174 be beneficial for monitoring the success of systemic chemotherapy in the treatment of various tubero
175 ions of this disease, as well as the role of systemic chemotherapy in treatment of unresectable disea
176 patients (75%) were treated with neoadjuvant systemic chemotherapy in whom 32 (36%) were considered t
178 t had progressed after at least two lines of systemic chemotherapy including at least one platinum-co
180 FUDR plus dexamethasone (Dex) and concurrent systemic chemotherapy including oxaliplatin or irinoteca
181 described as having several advantages over systemic chemotherapy, including reducing systemic toxic
182 Localized disease was treated with combined systemic chemotherapy, including rituximab and radiation
184 or the measurement of DAEs in the context of systemic chemotherapy interventions in clinical trials.
185 of age with nonmetastatic medulloblastoma by systemic chemotherapy, intraventricular methotrexate, an
186 ectal cancer complete postoperative adjuvant systemic chemotherapy, irrespective of tumor downstaging
191 nt of the disease and understand response to systemic chemotherapy is limited with current imaging ap
193 However, there is general agreement that systemic chemotherapy is rarely an effective form of man
198 th an isolated CNS relapse were treated with systemic chemotherapy known to enter into the CSF and in
199 AIDS-related Kaposi's sarcoma (AIDS-KS) with systemic chemotherapy, less toxic therapies are needed.
200 ansitional-cell carcinoma (TCC) treated with systemic chemotherapy may be a consequence of pretreatme
201 trinsic resistance of melanoma metastases to systemic chemotherapy may be due, in part, to the cells'
203 imary tumor can often be treated by local or systemic chemotherapy, metastatic dissemination is gener
207 (n = 1), external beam radiotherapy (n = 1), systemic chemotherapy (n = 4), and observation (patient
210 ients who received surgery and postoperative systemic chemotherapy, no significant differences were o
212 ctreotide, interferon, and both arterial and systemic chemotherapy, of which only chemoembolisation i
213 was to evaluate the influence of neoadjuvant systemic chemotherapy on patients with colorectal carcin
215 dvanced RCC treated on 24 clinical trials of systemic chemotherapy or cytokine therapy were the subje
218 ients assigned to adjuvant HIPEC followed by systemic chemotherapy or only adjuvant systemic chemothe
219 t of 15 HIV-1-infected individuals receiving systemic chemotherapy or subsequent autologous stem cell
220 ressive disease after receiving at least one systemic chemotherapy or within 12 months of neoadjuvant
221 those recurrent after surgery, radiotherapy, systemic chemotherapy, or topical chemotherapy) vs treat
222 , young patients were more likely to receive systemic chemotherapy, particularly multiagent regimens,
223 INTERPRETATION: Traditional neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade (
225 cervical cancer not previously treated with systemic chemotherapy (previous radiosensitising chemoth
226 A total of 23 patients (95.8%) received systemic chemotherapy prior to pembrolizumab, and the me
230 urothelial cancer who had received one prior systemic chemotherapy regimen for advanced disease and h
236 led that survivors who had been treated with systemic chemotherapy scored significantly lower on over
237 led that survivors who had been treated with systemic chemotherapy scored significantly lower on the
239 eritoneal metastases, failure of neoadjuvant systemic chemotherapy should not constitute an absolute
240 chemotherapy include early administration of systemic chemotherapy, shrinkage of primary tumor, and p
241 domized EORTC 62961 phase-III trial, RHT and systemic chemotherapy significantly improved local progr
243 traocular retinoblastomas after radiation or systemic chemotherapy than has been reported in the lite
244 ven via intrathecal route concomitantly with systemic chemotherapy that crosses the blood-brain barri
245 solated CNS relapse of ALL were treated with systemic chemotherapy that effectively penetrates into t
247 occurred in 9 of 40 (23%) patients receiving systemic chemotherapy; the most common of these effects
248 fin photodynamic therapy in combination with systemic chemotherapy therapies and oral corticosteroids
249 noma, no resection of the primary tumor, and systemic chemotherapy, this study investigated the incid
251 d in association with concomitant multiagent systemic chemotherapy to children younger than 3 years w
252 the COX2 and YAP1 pathways concurrently with systemic chemotherapy to improve the clinical management
253 ples from patients that have been exposed to systemic chemotherapy to infer the genomic landscape of
256 tance and toxicities often limit benefits of systemic chemotherapy used to treat metastatic sarcomas.
257 with Reese-Ellsworth eye groups 1, 2, or 3, systemic chemotherapy used with local ophthalmic therapi
258 floxuridine (HAI-FUDR) in addition to modern systemic chemotherapy using oxaliplatin or irinotecan re
262 on, the combination of dl1520 infection with systemic chemotherapy was assessed in these tumor xenogr
264 of SIR-Spheres therapy with modified FOLFOX4 systemic chemotherapy was conducted in patients with ino
265 chronous unresectable metastases, PTR before systemic chemotherapy was not associated with prolonged
266 s of patients with isolated PVRL, the use of systemic chemotherapy was not proven to prevent CNSL and
267 until no further benefit could be achieved; systemic chemotherapy was sometimes used as a palliative
270 rty-four patients who had not received prior systemic chemotherapy were randomized to either arm of t
271 Patients with stage IV TCC and no prior systemic chemotherapy were randomized to GC (gemcitabine
272 cer who had not been previously treated with systemic chemotherapy were recruited from 91 academic me
273 completeness of CRS and the use of adjuvant systemic chemotherapy were the only significant prognost
274 chial, or mediastinal metastases, who failed systemic chemotherapy, were enrolled in this prospective
275 bladder has traditionally been treated with systemic chemotherapy, which is most often platinum-base
276 e but applicable to only a few patients, and systemic chemotherapy, which is of uncertain benefit but
278 surgical resection of the primary tumour and systemic chemotherapy, which provides considerably longe
279 , extended intrathecal therapy and intensive systemic chemotherapy will, in all likelihood, replace c
280 tumors of the gynecologic tract will require systemic chemotherapy with a platinum agent and etoposid
282 entral nervous system lymphoma are employing systemic chemotherapy with drugs that penetrate the bloo
284 carcinoma (iCCA) confined to the liver after systemic chemotherapy with gemcitabine-cisplatin (gem-ci
287 le disease, consideration should be given to systemic chemotherapy with or without a biologic agent o
289 minant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; how
290 roaches based on the site of malignancy, but systemic chemotherapy with or without radiation plays a
291 with HAI floxuridine and dexamethasone plus systemic chemotherapy with oxaliplatin and irinotecan.
293 tal radiation of 30 gray in conjunction with systemic chemotherapy with rituximab can achieve disease
294 re randomized trials should compare HAI plus systemic chemotherapy with systemic therapy alone to ass
298 able site-directed chemotherapy, rather than systemic chemotherapy, with 'real time' drug decaging at
300 he proposed modified regimen of conventional systemic chemotherapy without serial intraventricular me